Centrelink issues ATO tax refund warning: ‘Repay it'
Services Australia, which is the body in charge of Centrelink, is legally obligated to recover money that's owed to it. That means it will sometimes use your tax refund to reduce the amount you owe.
'If you have a debt with us at tax time, we may use your tax refund to repay it,' Services Australia said.
'We may do this if you're not actively making repayments towards your debt or you don't have a repayment arrangement in place.'
RELATED
Centrelink alert for 240,000 Aussie families as some see popular payment stopped
ATO tax return warning for 2 million Aussies over dangerous act
Warning for working from home Aussies over common practice
Services Australia said it could use your tax refund to repay your debt at tax time if you receive a Family Tax Benefit or Child Care Subsidy, you're a former customer and not making any repayments on your debt, or you have an overdue Child Support debt.
It will avoid recovering debts with tax return refunds if your debt repayments have been paused due to a disaster or emergency event, or a pending formal review.
Services Australia said it will check for overpayments or existing Centrelink debts when it balances your Family Tax Benefit and Child Care Subsidy.
Services Australia starts balancing Family Tax Benefit in July and Child Care Subsidy in mid-August.
It will then recover any overpayments or existing debts you owe before paying you any top ups, Family Tax Benefit supplements or lump sums.
For people who owe child support, or have been overpaid child support, it will use a tax refund to pay any outstanding amounts directly.
It has urged parents who would experience hardship to contact it on the Child Support enquiry line before they lodge their tax returns.
Former Centrelink recipients who haven't made an arrangement to repay their debt will be sent a letter if money is taken from their tax refund.
It will also appear on your Notice of Assessment from the ATO as a 'Credit Offset to Centrelink'.
You can find out more about repaying money owed to Centrelink here.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ASX Ltd (ASXFF) (FY25) Earnings Call Highlights: Strong Revenue Growth and Dividend Increase ...
Operating Revenue: $1.11 billion, up 7% year-over-year. Underlying Net Profit After Tax (NPAT): Increased by 7.5%. Statutory Profit: Up by 6%. Final Dividend: $1.121 per share, fully franked, with a total dividend of $2.233 per share, up 7.4%. EBITDA Margin: Increased by 70 basis points to 62.8%. Return on Equity (ROE): Up by 60 basis points to 13.6%. Total Expenses: $460.3 million, up 7.2%. Net Interest Income: $86.8 million, up 13.2%. Listings Revenue: Stable at $208 million. Markets Revenue: $349.2 million, up 10.7%. Technology and Data Revenue: $275.6 million, up 8%. Securities and Payments Revenue: $274.4 million, up 7.4%. Capital Expenditure (CapEx): $176 million for FY25. Guidance for FY26 Expenses Growth: 14% to 19%, including ASIC inquiry costs. Guidance for FY26 CapEx: Between $170 million and $180 million. Warning! GuruFocus has detected 5 Warning Signs with ASXFF. High Yield Dividend Stocks in Gurus' Portfolio This Powerful Chart Made Peter Lynch 29% A Year For 13 Years How to calculate the intrinsic value of a stock? Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points ASX Ltd (ASXFF) reported a strong financial performance for FY25 with operating revenue of $1.11 billion, up 7% from the previous year. The company declared a fully franked final dividend of $1.121 per share, reflecting a payout ratio of 85% of underlying NPAT. ASX Ltd (ASXFF) achieved an EBITDA margin increase of 70 basis points to 62.8%, with plans for further margin expansion. The company is making significant progress in its technology modernization program, including the successful launch of Release 15 for its Cash Market Trading project. ASX Ltd (ASXFF) is actively pursuing customer-driven growth opportunities, including enhancements to market quality and new data products. Negative Points ASX Ltd (ASXFF) faces increased operating expenses due to the ASIC inquiry, with an expected additional cost of $25 million to $35 million in FY26. The company is not yet where it wants to be in terms of operational risk management and resilience, necessitating the Accelerate program. There is ongoing uncertainty around the timing of interoperability between e-conveyancing platforms, impacting the Sympli joint venture. ASX Ltd (ASXFF) is experiencing higher technology expenses, driven by increased software licensing fees and costs related to technology projects. The company is under scrutiny from ASIC, which has launched a compliance assessment and inquiry into ASX Ltd (ASXFF)'s governance, capability, and risk management frameworks. Q & A Highlights Q: Can you elaborate on the spread benefit on the collateral balances and the trajectory for FY26? A: Andrew Tobin, CFO: The spread has been extending slightly, with opportunities taken at the short end of the curve. We guide to around 16 basis points for FY26, depending on the persistence of these opportunities. Q: What is your forward view on the annual listing fees, given the current market conditions? A: Andrew Tobin, CFO: The net capital added to the market has been positive, indicating a strong trend in initial and secondary fees. The roll-off profile and monthly market activity reports can help model future outcomes. Q: How do you view the sustainability of the dividend payout given the cash position and expenses? A: Andrew Tobin, CFO: The Board considers the dividend payout policy each period, currently set at 80% to 90%. With increasing amortization, the cash flow remains positive, supporting the dividend sustainability. Q: What are the potential risks for costs in FY27, especially with the ASIC inquiry? A: Helen Lofthouse, CEO: The $25 million to $35 million for the ASIC inquiry is expected to be specific to FY26. We have a transformational strategy in place, and it's not appropriate to prejudge the inquiry's outcome. Q: Can you explain the gap between market business revenue growth and volume growth? A: Helen Lofthouse, CEO: The gap is due to a mix shift and increased volume rebates. Slower performance in commodities and significant growth in rates, which have lower price points, contributed to this dynamic. Q: How do you view the potential competition in corporate listings and its impact on annual listing fees? A: Helen Lofthouse, CEO: The market is already competitive with choices among exchanges and public/private markets. Our pricing and value proposition are set within this competitive context. Q: What is the impact of the new pricing policy for clearing and settlement from July 1? A: Helen Lofthouse, CEO: The new pricing model replaces the rebate structure, with no fee changes expected for the next couple of years. It uses a building block method, commonly used for infrastructure services. Q: How should we think about the costs associated with the ASX Accelerate program? A: Helen Lofthouse, CEO: The program increases the pace of key strategic work, adding rigorous planning and delivery expertise. It's a wrap around existing plans rather than a separate set of initiatives. Q: What feedback have you received on the new pricing approach for clearing and settlement? A: Helen Lofthouse, CEO: The approach was consulted on last year, with adjustments made based on feedback. It has been reviewed by stakeholder committees and regulators, with broad comfort achieved. Q: How do you view the growth potential for the information services business? A: Helen Lofthouse, CEO: We see further growth opportunities in data, with new products launched and more in development. While we don't guide to specific growth targets, it's a key area of focus. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Orora Ltd (ORRAF) (FY 2025) Earnings Call Highlights: Strong EBITDA Growth Amidst Challenges
EBITDA: $418.8 million, an increase of 19.4%. EBIT: $262.1 million, an increase of 9.5%. Statutory NPAT: $973.1 million, including profit on sale for OPS. Continuing NPAT: $151.1 million. EPS: $0.114 per share. Operating Cash Flow: $333.6 million. Net Debt: $254 million with leverage at 0.7x EBITDA. Final Dividend: $0.05 per share unfranked, total dividend for the year $0.10. Cans Revenue Growth: 12.1% higher, or 8.9% excluding aluminum prices impact. Cans Volume Growth: 6% for the year. Saverglass Revenue Decrease: 16.5% with volumes down 12%. Gawler Revenue Increase: 1.5%. Group Revenue: Increased 24% to $2.1 billion. Free Cash Flow Available to Shareholders: $97 million. CapEx: $263 million for FY25, expected $200 million for FY26. Dividend Payout Ratio: 69% of continuing operations for the half. Warning! GuruFocus has detected 7 Warning Signs with ORRAF. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Orora Ltd (ORRAF) reported a strong EBITDA increase of 19.4% to $418.8 million, driven by a full year's contribution from Saverglass. The Cans business experienced a 6% volume growth, with revenue increasing by 12.1%, excluding the pass-through impact of aluminum prices. The company's balance sheet remains robust with net debt at $254 million and leverage at 0.7x EBITDA, supporting ongoing shareholder returns. Orora Ltd (ORRAF) declared a final dividend of $0.05 per share, bringing the total dividend for the year to $0.10, and has made significant progress on its share buyback program. The company is making substantial investments in capacity expansions, with a $350 million capital spend expected to deliver an incremental $50 million of EBIT by FY30. Negative Points The operating environment for the glass business, particularly Saverglass, remains challenging due to ongoing tariff issues and a 16.5% revenue decrease. The Gawler facility was impacted by the G3 furnace shutdown, contributing to a decline in EBIT. Higher depreciation costs, particularly from Saverglass, have partly offset EBITDA growth. The company faces potential challenges from US tariffs on EU production, which could impact Saverglass' operations. Orora Ltd (ORRAF) anticipates additional corporate costs of $7 million in FY26, which could temper EBIT growth. Q & A Highlights Q: Can you elaborate on the volume growth expectations for Saverglass in FY26 and whether it will be consistent across both halves of the year? A: Brian Lowe, CEO: The volume growth in the second half of FY25 was primarily due to new business in wine and champagne. We are not expecting a significant pickup in underlying consumer demand but are focusing on growing new business. The timing of demand is variable, and while historically the first half is stronger, it is difficult to project at the moment. We expect growth in specific segments other than spirits, which have a longer turnaround time. Q: Why does the guidance for Saverglass imply only slight EBITDA growth despite higher volumes and cost reductions? A: Shaun Hughes, CFO: The slight increase in EBITDA is driven by cost actions and stable pricing. The mix shift towards wine and champagne, which have lower price points, affects the overall growth. We are assuming constant currency with FY25 for our outlook. Q: Saverglass performed better than expected in the second half. What drove this positive surprise? A: Shaun Hughes, CFO: The team successfully drove volume growth in wine and champagne, achieving a 9% increase between the first and second halves. This growth, along with cost reduction efforts, contributed to the better-than-expected performance. Q: How do you assess the risk of competitors moving into the ultra-premium segment of Saverglass? A: Brian Lowe, CEO: The ultra-premium segment remains stable, and we have not seen significant competitive pressure. The business model for ultra-premium is different, with unique configurations and quality standards. We are well-positioned, and our pricing is holding well. Q: Can you provide insights into the sustainability of cost reductions at Saverglass, especially with the network changes at Le Havre? A: Brian Lowe, CEO: Most cost reductions are sustainable, including the EUR9 million savings from the Le Havre furnace closure. We have also reduced structural costs and worked with suppliers to lower costs. The profit-sharing arrangement is based on business performance, and we aim to maintain the reduced cost base. Q: What are the key priorities for Orora in the next two to three years? A: Brian Lowe, CEO: The focus is on execution, particularly in the Cans business, where growth CapEx investments are nearing completion. For Saverglass, we aim to drive cost efficiency and instill global practices. We are not focusing on new areas but rather on optimizing current operations. Q: How do you plan to manage the impact of tariffs on Saverglass in FY26? A: Brian Lowe, CEO: The 15% tariff on EU production is a recent development, and we are yet to receive feedback from customers. Our outlook assumes steady underlying demand, and we are pursuing opportunities to grow volume independently of tariff impacts. Q: What factors give you confidence that demand for Saverglass is stabilizing? A: Brian Lowe, CEO: Customer-owned inventory levels have decreased significantly, indicating stabilization. Nielsen scan data shows a global decline in spirits demand, but we believe destocking is ending, and demand should stabilize to consumer levels. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
an hour ago
- Yahoo
Pro Medicus Ltd (PMCUF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Wins
Revenue Growth: Up just under 32%. Profit After Tax: Increased by approximately 40%. Underlying EBIT: Around 40% growth. Margins: Increased from mid-72% to 74%. Retained Earnings: Increased by about 36%. Dividend: Fully franked dividend of $0.30 per share, up 37.5%. Contract Wins: Seven contracts totaling $520 million. Contract Renewals: Two large contracts worth $130 million. Product Upgrades: Additional products with existing clients totaling $39 million. Forward Revenue: Increased from low $600 million to $948 million over a five-year window. Australian Business Growth: Grew just under 5%. Total Addressable Market (TAM): Updated to $670 million. Current Market Penetration: Estimated at about 10% and growing. Warning! GuruFocus has detected 5 Warning Signs with PMCUF. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Pro Medicus Ltd (PMCUF) reported a significant increase in key financial metrics, with revenue up nearly 32% and profit after tax up approximately 40%. The company secured seven new contracts totaling $520 million and renewed two large contracts worth $130 million, indicating strong sales performance. Pro Medicus Ltd (PMCUF) has maintained industry-leading margins, increasing from mid-72% to 74%, showcasing efficient cost management. The company has expanded its product portfolio with successful implementations of Visage 7 and Open Archive, transitioning clients from on-premise to cloud solutions. Pro Medicus Ltd (PMCUF) has made significant strides in AI and research collaborations, including agreements with UCSF, Mayo, and NYU, positioning itself for future growth in AI-driven healthcare solutions. Negative Points The pathology market is still emerging, and Pro Medicus Ltd (PMCUF) has not yet determined pricing for pathology exams, which could impact future revenue streams. The company faces competition from legacy systems and other vendors, with 90% of the market still using older technologies. There is uncertainty regarding the adoption rate of digital pathology, as the market is nascent and institutions are only beginning to consider digital solutions. Pro Medicus Ltd (PMCUF) has not yet penetrated the Chinese market due to regulatory and market dynamics, limiting its global expansion potential. The company acknowledges that it does not have a 100% hit rate on pipeline contracts, with some losses attributed to price competition and perceived cost. Q & A Highlights Q: Can you clarify the market size for the pathology product and how it compares to radiology? A: The pathology market is where radiology was about 20 years ago. It's slightly different because the bulk of pathology isn't image-based. The market size is a bit less than radiology, and it's still emerging. We believe our technology is well-suited for this expanding market, particularly with cloud storage capabilities. Q: How do you plan to maintain your technological leadership in AI given the democratization of software development? A: There are two streams of AI in our space: generative AI, which aids in reporting, and clinical AI, which requires rigorous validation. The clinical part still has significant barriers to entry, such as FDA clearance, which maintains our competitive edge. Q: What is the addressable market for cardiology, and how does it compare to radiology? A: Cardiology can be between 15% and 20% of radiology by value, depending on the organization. There are fewer tests, but each is more expensive. We expect to sell cardiology solutions back to existing clients and offer them to new clients as part of a full stack. Q: How is the revenue from an Open Archive upgrade like NYU's structured compared to a new full stack customer? A: Revenue from data migration is taken upfront based on milestones, while exam revenue is spread evenly over the contract period. For NYU, 10% to 15% of the total contract value is from data migration. Q: What are your thoughts on the competitive landscape, especially regarding cloud and AI? A: We believe we are the only company offering true cloud solutions at scale. While many competitors claim to have cloud and AI capabilities, we haven't seen any that match our level of implementation and scalability. Q: Can you discuss the potential for pathology adoption and the initial client reactions? A: The initial reaction to our pathology product has been positive, though it's early days. The large data sets in pathology align well with our strengths in cloud storage and streaming technology. We expect adoption to grow as institutions increasingly consider digital pathology. Q: What is the status of your contract renewals, and have you started discussions? A: We have started discussions for renewals, and they are proceeding similarly to past renewals. Some larger clients prefer to start conversations earlier, but the cadence varies by client. Q: How do you view the opportunity in Germany and Asia compared to the US? A: The US remains our primary market due to its size and fewer barriers to business. Europe and Asia present opportunities, particularly as cloud adoption increases, but the cost of sale is higher, and opportunities are smaller compared to the US. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
